Withdrawal of proposed incentive programs and revised proposal on board composition and fees ahead of AGM in OssDsign
The board of directors of OssDsign AB, following discussions with a larger group of major shareholders, announces the withdrawal of the proposed incentive programs and the nomination committee’s revised proposal as regards election of and fees payable to board members ahead of the annual general meeting.
PRESS RELEASE
OssDsign AB
Uppsala, 24 June, 2024
On 24 May 2024, the notice to OssDsign’s annual general meeting, to be held on 25 June 2024 in Stockholm, was published. In the notice, two (2) different share related incentive programs were proposed for employees and contractors and board members, respectively (items 13 and 15 in the proposed agenda). Following discussions with a larger group of major shareholders, the board of directors and shareholders have decided to withdraw the proposed resolutions on incentive programs with the intention to present new proposed incentive program(s) for decision at a future general meeting.
Further, following discussions with a larger group of major shareholders, the nomination committee has decided to present a revised proposal as regards election of and fees payable to board members (items 10-12 in the proposed agenda). Instead of re-election of all six (6) board members, the nomination committee proposes re-election of four (4) board members (Simon Cartmell, Newton Aguiar, Viktor Drvota and Jill Schiaparelli) and new-election of one (1) board member (Christer Fåhraeus). Consequently, the board is proposed to be composed of five (5) ordinary members without deputy members until the end of the next general meeting. SEK 300,000 is proposed to be paid to the new board member resulting in a total amount (to the entire board) of SEK 1,300,000 (instead of SEK 1,500,000) of which SEK 400,000 shall be paid to the chairman (Simon Cartmell is still proposed to be re-elected as chairman) and SEK 300,000 to each of the other board members except for Viktor Drvota to whom no board fee is proposed to be paid (considering that he is representing an institutional investor). Following the annual general meeting, the board (in consultation with the nomination committee) intends to initiate a recruitment process for another new board member to be proposed for election at a future general meeting.
Information about Christer Fåhraeus
Born in 1965. Christer Fåhraeus has thirty years of experience as CEO and board member in listed and unlisted companies in Life Science and Tech. He is also the founder of companies such as CellaVision AB, FlatFrog Laboratories AB, EQL Pharma AB, Anoto Group AB, Precise Biometrics AB, Fåhraeus Startup and Growth AB. Christer Fåhraeus holds a Medical Candidate and Ph.D. in Neurophysiology from the Faculty of Medicine at Lund University and a Master of Science in Medical Engineering from the University of California San Diego (USA). Currently, Christer Fåhraeus is Chairman of FSG Fund II AB, Fåhraeus Startup & Growth AB, and ApoEco Sverige AB. Board member of Airsonett AB, CellaVision AB, Checkin.com Group AB, FlatFrog Laboratories AB, Melius Pharma AB, and Bionamic AB. Previous assignments include Chairman of Amniotics AB (publ), Respiratorius AB (publ), Uman Sense AB, and Bionamic AB. Board member of Gasporox AB (publ), IntuiCell AB, LU Holding AB, RECCAN AB (publ), ScandiDos AB, and Serstech AB. Christer Fåhraeus is a partner in FSG Fund II, which holds 6 percent of the total number of shares and votes in the company. Christer Fåhraeus is independent of OssDsign and its executive management and is independent in relation to major shareholders in OssDsign (defined as shareholders controlling 10 percent or more of the total number of shares or votes in the company).
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Mob: +46 73 382 43 90
morten.henneveld@ossdsign.com
Certified Adviser:
Carnegie Investment Bank AB (publ) is the company’s Certified Adviser.
Publication
This information was submitted for publication, through the agency of the contact person set out above, on 24 June 2024, 14:00 CET.
About OssDsign
OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give patients back the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com
Certified Adviser
The Company’s Certified Adviser is Carnegie Investment Bank AB (publ)
About OssDsign
OssDsign is a developer and global provider of next generation orthobiologics products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they deserve. The company has a strong presence in the U.S. market. OssDsign's share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
Tags: